Study guide

3.6 Biochemical & Inflammatory Marker Interpretation

CDR CSO Board Certified Specialist in Oncology Nutrition Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the CDR CSO Exam & Certification Logistics 1.2 How to Navigate and Master This Study Guide

2 Chapter 2: Cancer & Cancer Treatment Modalities

2.1 Cancer Biology, Pathophysiology, & Carcinogenesis 2.2 Staging, Grading, & Surgical Oncology Interventions 2.3 Radiation Therapy Modalities & Radiation Toxicities 2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging 2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy 2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)

3 Chapter 3: Comprehensive Nutrition Assessment & Malnutrition Staging

3.1 Patient-Generated Subjective Global Assessment (PG-SGA) 3.2 GLIM Criteria for Malnutrition Diagnosis in Oncology 3.3 Cancer Cachexia Staging & Pathophysiology (Fearon Consensus) 3.4 Estimating Energy & Protein Requirements (ESPEN Guidelines) 3.5 Anthropometrics & Body Composition Analysis (DEXA, BIA, CT) 3.6 Biochemical & Inflammatory Marker Interpretation 3.7 Nutrition-Focused Physical Exam (NFPE) in Oncology 3.8 Medical, Oncologic, and Treatment History Review 3.9 Diet and Lifestyle History: Methods and Interpretation 3.10 Cultural, Psychosocial, and Socioeconomic Factors

4 Chapter 4: Nutrition-Impact Side Effect Management & Pharmacotherapy

4.1 Upper GI Symptoms: Anorexia, Early Satiety, Nausea, & Vomiting 4.2 Oral & Mucosal Toxicities: Stomatitis, Mucositis, Dysgeusia, & Xerostomia 4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation 4.4 Pancreatic Exocrine Insufficiency & PERT Dosing Protocols 4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics 4.6 Oncologic Emergencies: Tumor Lysis, Hypercalcemia, & Superior Vena Cava Syndrome

5 Chapter 5: Specialized Nutrition Interventions, Disease-Site MNT & Care Coordination

5.1 Enteral Nutrition: Access, Indications, & Formula Selection 5.2 Prophylactic Enteral Tubes in Head & Neck Cancer 5.3 Parenteral Nutrition in Oncology: Indications & Management 5.4 Disease-Site MNT: Head & Neck, Esophageal, & Gastric Cancers 5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers 5.6 Disease-Site MNT: Hematologic Malignancies & HSCT 5.7 Refeeding Syndrome & Cyclic Nutrition Support Protocols 5.8 Referrals, Care Coordination, and Transitions of Care 5.9 Monitoring, Evaluation, and Nutrition Outcomes

6 Chapter 6: Patient Education, Counseling, & Herbal/Supplement Safety

6.1 Patient Counseling & Motivational Interviewing 6.2 Managing Sensory Alterations & Taste Changes 6.3 Complementary & Alternative Medicine (CAM) in Oncology 6.4 Dietary Supplement & Herbal Safety during Cancer Therapy 6.5 Key Drug-Nutrient Interactions in Oncology

7 Chapter 7: Cancer Survivorship, Palliative Nutrition, & End-of-Life Ethics

7.1 Food Safety & Neutropenic Dietary Evidence 7.2 Cancer Survivorship: AICR/WCRF Guidelines & Lifestyle 7.3 Weight Management & Metabolic Health in Survivorship 7.4 Palliative Nutrition & Goals of Care Alignment 7.5 End-of-Life Ethical Considerations & Bioethics

3.6 Biochemical & Inflammatory Marker Interpretation

Key Takeaways Explain This Topic AI

Traditional visceral proteins (serum albumin, prealbumin, transferrin) are negative acute-phase reactants regulated by systemic inflammation and vascular endothelial leak, rendering them invalid as direct markers of dietary protein intake or somatic muscle mass.

C-Reactive Protein (CRP) is a positive acute-phase reactant synthesized by hepatocytes under direct Interleukin-6 (IL-6) stimulation; levels >10 mg/L quantify active systemic inflammation and tumor catabolism.

The modified Glasgow Prognostic Score (mGPS) combines CRP and Albumin into an evidence-based prognostic index (mGPS 0 to 2), where an mGPS score of 2 (CRP >10 mg/L & Albumin <35 g/L) independently predicts severe cachexia, chemotherapy resistance, and shortened overall survival.

Prevention of fatal Refeeding Syndrome requires baseline assessment and frequent monitoring of serum phosphate, potassium, and magnesium upon reintroducing nutrition in severely malnourished patients.

Interpretation of organ function labs in oncology must account for muscle wasting (which artificially lowers creatinine) and tumor involvement (distinguishing hepatic from bone ALP via GGT).

Last updated: August 2026

Biochemical & Inflammatory Marker Interpretation

Biochemical assessment in oncology nutrition requires a thorough understanding of inflammatory pathophysiology. Historical reliance on serum visceral proteins (such as albumin and prealbumin) as direct indicators of nutritional adequacy has been disproven by modern clinical science. Instead, hepatic acute-phase protein responses governed by systemic cytokines dictate serum protein levels. Inflammatory scoring systems, such as the modified Glasgow Prognostic Score (mGPS) , provide validated objective prognostic data for cancer management.

The Paradigm Shift: Visceral Proteins as Negative Acute-Phase Reactants

Serum visceral proteins—including Albumin (half-life ∼ 18 − 20 \sim 18 - 20 ∼ 18 − 20 days), Prealbumin / Transthyretin (half-life ∼ 2 − 3 \sim 2 - 3 ∼ 2 − 3 days), and Transferrin (half-life ∼ 8 − 10 \sim 8 - 10 ∼ 8 − 10 days)—were historically assumed to measure somatic protein stores and dietary protein intake. However, consensus guidelines from ASPEN and ESPEN affirm that these proteins function primarily as Negative Acute-Phase Reactants controlled by systemic inflammation: +-----------------------------------------------------------------------+

  • | HEPATIC ACUTE-PHASE RESPONSE IN CANCER |
  • +-----------------------------------------------------------------------+
  • | SYSTEMIC CYTOKINE SURGE (IL-6, TNF-alpha, IL-1beta) |
  • | |
  • | 1. Hepatic Reprogramming: |
  • | - DOWNREGULATES gene expression for Albumin & Prealbumin |
  • | - UPREGULATES gene expression for Positive Reactants (CRP, Fibrinogen)|
  • | |
  • | 2. Vascular Endothelial Permeability: |
  • | - Cytokines open endothelial tight junctions |
  • | - Causes rapid Transcapillary Extravasation of Albumin into gut/tissue|
  • | |
  • | CLINICAL TAKEAWAY: A low serum albumin/prealbumin indicates SEVERE |
  • | INFLAMMATION, NOT lack of dietary protein. Supplementing high protein|
  • | will NOT raise serum albumin while active inflammation persists. |
  • +-----------------------------------------------------------------------+
  • Positive Acute-Phase Reactants & C-Reactive Protein (CRP)

C-Reactive Protein (CRP) is a Positive Acute-Phase Reactant synthesized by hepatocytes under direct stimulation by Interleukin-6 (IL-6). Normal serum CRP is ≤ 10 mg/L \le 10\text{ mg/L} ≤ 10 mg/L (or ≤ 1.0 mg/dL \le 1.0\text{ mg/dL} ≤ 1.0 mg/dL ). Elevated serum CRP ( > 10 mg/L >10\text{ mg/L} > 10 mg/L ) provides an objective, quantitative biomarker of systemic inflammation, active tumor catabolism, and cachexia progression.

The Modified Glasgow Prognostic Score (mGPS)

The modified Glasgow Prognostic Score (mGPS) is an evidence-based, inflammation-based prognostic scoring system validated across multiple solid tumor types (gastrointestinal, non-small cell lung, renal cell, gynecologic, head and neck cancers).

Scoring Algorithm & Rules

Clinical Biomarker Findings Points Assigned Clinical Risk & Prognostic Category

CRP ≤ 10 mg/L \le 10\text{ mg/L} ≤ 10 mg/L AND Albumin ≥ 35 g/L \ge 35\text{ g/L} ≥ 35 g/L (or < 35 g/L <35\text{ g/L} < 35 g/L without CRP elevation) Score 0 Low Risk / Minimal Systemic Inflammation

CRP > 10 mg/L > 10\text{ mg/L} > 10 mg/L AND Albumin ≥ 35 g/L \ge 35\text{ g/L} ≥ 35 g/L Score 1 Moderate Risk / Active Systemic Inflammation

CRP > 10 mg/L > 10\text{ mg/L} > 10 mg/L AND Albumin < 35 g/L < 35\text{ g/L} < 35 g/L Score 2 High Risk / Severe Systemic Inflammation & Hypoalbuminemia

The Normal CRP Rule: If serum CRP is normal ( ≤ 10 mg/L \le 10\text{ mg/L} ≤ 10 mg/L ), a low serum albumin ( < 35 g/L <35\text{ g/L} < 35 g/L or < 3.5 g/dL <3.5\text{ g/dL} < 3.5 g/dL ) receives an mGPS score of 0 . Hypoalbuminemia in the absence of elevated CRP is attributed to non-inflammatory causes (e.g., fluid overload, nephrotic syndrome, hepatic synthetic failure) rather than cancer-driven systemic inflammation.

Clinical Significance of mGPS 2: Strong independent predictor of shortened overall survival, resistance to chemotherapy, severe skeletal muscle wasting, and high risk of grade 3–4 treatment toxicities.

Refeeding Syndrome & Electrolyte Monitoring

When introducing nutritional refeeding (oral, enteral, or parenteral) in severely malnourished oncology patients, rapid carbohydrate administration triggers a massive insulin surge, driving electrolytes intracellularly:

Hallmark Refeeding Triad:

Hypophosphatemia (severe drops < 1.0 mg/dL <1.0\text{ mg/dL} < 1.0 mg/dL lead to cardiac arrhythmias, impaired myocardial contractility, respiratory failure, and encephalopathy).

Hypokalemia (risk of fatal cardiac arrest and paralytic ileus).

Hypomagnesemia (tetany, tremors, cardiac arrhythmias, refractory hypokalemia/hypocalcemia).

Monitoring & Repletion Protocol: Baseline K+, PO4-, and Mg2+ must be checked prior to initiating nutrition support and monitored daily for 5–7 days, with aggressive electrolyte repletion before advancing caloric goals.

Organ Function & Oncology-Specific Laboratory Pitfalls

Renal Function (BUN, Creatinine, eGFR): Creatinine is derived from non-enzymatic degradation of skeletal muscle creatine. In patients with severe muscle wasting (sarcopenia), serum creatinine is artificially suppressed (e.g., 0.4 mg/dL 0.4\text{ mg/dL} 0.4 mg/dL ), producing a falsely elevated eGFR that masks underlying renal impairment. Cystatin C should be ordered as a non-muscle-dependent marker of renal clearance.

Liver Enzymes & Bone Biomarkers: Elevated Alkaline Phosphatase (ALP) must be evaluated alongside Gamma-Glutamyl Transferase (GGT) or ALP isoenzymes to distinguish hepatic/biliary obstruction (elevated GGT) from osteoblastic bone metastases (normal GGT).

Complete Blood Count (CBC) & Iron Status: Anemia of chronic disease is characterized by low serum iron, low TIBC, and elevated ferritin ( > 100 − 300 ng/mL >100 - 300\text{ ng/mL} > 100 − 300 ng/mL ) driven by hepcidin elevation. True iron deficiency requires evaluation of Soluble Transferrin Receptor (sTfR) or sTfR-ferritin index.

  • Comprehensive Worked Clinical Case Study
  • Patient Scenario

A 63-year-old male with metastatic esophageal adenocarcinoma is admitted to the oncology unit with severe weight loss ( 14 % 14\% 14% over 3 months) and dysphagia. Nutritional re-feeding via nasogastric tube is planned.

Admission Labs: CRP = 42 mg/L 42\text{ mg/L} 42 mg/L , Albumin = 2.6 g/dL 2.6\text{ g/dL} 2.6 g/dL ( 26 g/L 26\text{ g/L} 26 g/L ), Prealbumin = 8 mg/dL 8\text{ mg/dL} 8 mg/dL , Potassium = 3.2 mEq/L 3.2\text{ mEq/L} 3.2 mEq/L , Phosphate = 1.8 mg/dL 1.8\text{ mg/dL} 1.8 mg/dL , Magnesium = 1.4 mg/dL 1.4\text{ mg/dL} 1.4 mg/dL , Serum Creatinine = 0.5 mg/dL 0.5\text{ mg/dL} 0.5 mg/dL . CT scan confirms severe L3 muscle wasting.

Clinical Evaluation & Management

mGPS Calculation: CRP > 10 mg/L >10\text{ mg/L} > 10 mg/L ( 42 42 42 ) AND Albumin < 35 g/L <35\text{ g/L} < 35 g/L ( 26 26 26 ) → \rightarrow → mGPS Score 2 (Severe Systemic Inflammation, High Risk of Mortality).

Refeeding Risk Assessment: Patient is at extreme risk for Refeeding Syndrome due to severe malnutrition and baseline hypokalemia ( 3.2 3.2 3.2 ), hypophosphatemia ( 1.8 1.8 1.8 ), and hypomagnesemia ( 1.4 1.4 1.4 ).

Immediate Action Protocol:

Step 1: Hold initiation of full caloric enteral nutrition.

Step 2: Administer IV electrolyte repletion (IV Potassium Chloride, IV Sodium/Potassium Phosphate, IV Magnesium Sulfate) to normalize serum levels.

Step 3: Administer IV Thiamine ( 200 − 300 mg 200 - 300\text{ mg} 200 − 300 mg daily) prior to starting carbohydrate feeding.

Step 4: Initiate enteral nutrition at a cautious rate of 10 kcal/kg/day 10\text{ kcal/kg/day} 10 kcal/kg/day ( ∼ 600 kcal/day \sim 600\text{ kcal/day} ∼ 600 kcal/day ), gradually advancing over 4–7 days while monitoring electrolytes daily.

Loading diagram... mGPS Calculation & Refeeding Electrolyte Pathway